Alger, E., Lee, S. M., Cheung, Y. K., & Yap, C. (2024). U-PRO-CRM: designing patient-centred dose-finding trials with patient-reported outcomes. ESMO Open, 9(7), 103626. https://doi.org/10.1016/j.esmoop.2024.103626

Felip, E., Shu, C. A., Aguilar, A., Tang, K.-J., García Campelo, M. R., Lee, K.-Y., Delmonte, A., Sabari, J., Girard, N., Mansfield, A. S., Park, K., Zhou, C., Xia, K., Bhattacharya, A., Wade, M., Baig, M., Agrawal, T., Mahadevia, P., Knoblauch, R. E., & Sanborn, R. E. (2024). 2MO Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON. ESMO Open, 9, 102581. https://doi.org/10.1016/j.esmoop.2024.102581

Schöffski, P., Lorusso, P., Yamamoto, N., Reichardt, P., Schwartz, L., Dercle, L., Zhao, B., Chitalia, R., Montgomery, G., Hu, C., Landsteiner, H. T., Jayadeva, G., & Gounder, M. (2024). 56O A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma. ESMO Open, 9, 102446. https://doi.org/10.1016/j.esmoop.2024.102446

He, P., Gambhire, D., Zhou, H., Ma, X., Emura, Y., Laadem, A., Leung, D., Bates, S. E., Fojo, A. T., & Rixe, O. (2024). 76P Utilization of g score in early oncology drug development: Impact on study design and early go/no-go decision. ESMO Open, 9, 102304. https://doi.org/10.1016/j.esmoop.2024.102304

Graff, S. L., Bansal, R., Adeyelu, T., Elliott, A., Bustos, M., Rodriguez, E., Accordino, M., Meisel, J., Gatti-Mays, M., Hsu, E., Lathrop, K. I., Kaklamani, V., Oberley, M., Sledge, G., & Sammons, S. (2023). 215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer. ESMO Open, 8(1), 101404. https://doi.org/10.1016/j.esmoop.2023.101404

Ozturk, D. G., Özkan, H., Akcan, U., & Korkmaz, G. (2023). 23P Synthetic lethality by targeting RHEB in ARID1A-mutated luminal breast cancer. ESMO Open, 8(1), 100989. https://doi.org/10.1016/j.esmoop.2023.100989